Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04429568
Other study ID # 17-24117
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 30, 2020
Est. completion date June 30, 2024

Study information

Verified date April 2024
Source University of California, San Francisco
Contact Lisa Lawrence
Phone (415) 608-4864
Email Lisa.Lawrence@ucsf.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized, crossover study enrolling experienced dual cannabis-tobacco smokers (N=18) to describe the differences in THC and toxicant exposure, examining pharmacokinetic, subjective, and cardiovascular effects from smoking and vaping dry herb cannabis. This study will also examine the differences in toxicant exposure and cardiovascular disease risk between smoking cannabis and smoking tobacco cigarettes.


Description:

Experienced dual cannabis-tobacco smokers will participate in a within-subject crossover study with three blocks: smoked cannabis (purchased by participants from a local dispensary), dry herb cannabis vaporizer, and usual brand tobacco cigarette. Each block will consist of 2 consecutive days on an inpatient research ward. The first inpatient day of each block will comprise of two sessions: (1) The first session will be a standardized bout to compare pharmacokinetic, physiologic, and subjective effects of cannabis and tobacco use; (2) after 6 hours of abstinence, the second session will be ad libitum access to the assigned product for 2 hours to compare subjective effects (reward, satisfaction, craving reduction) and use patterns. The second inpatient day will consist of ad libitum use of the assigned product from 8:00 in the morning to midnight. An abstinence day will be added after the second day of the last block to assess exposure and effects biomarkers during a period of abstinence from cannabis (smoked/vaped) or tobacco.


Recruitment information / eligibility

Status Recruiting
Enrollment 18
Est. completion date June 30, 2024
Est. primary completion date June 30, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years and older
Eligibility Inclusion Criteria: - Healthy on the basis of medical history and limited physical examination, as described below: Heart rate < 105 beats per minute (BPM); Systolic Blood Pressure < 160 and > 90*; Diastolic Blood Pressure < 100 and > 50* *Considered out of range if both machine and manual readings are above/below these thresholds. - Current regular user of cannabis who smokes cannabis as joint or blunt at least 3 times a week for past 3 months - History of cannabis vaporizer use or willingness to use the vaporizer in the study - Current tobacco cigarette use who smokes = 5 cigarettes per day - Saliva cotinine = 50 ng/ml - Test positive for D-9-tetrahydrocannabinol (THC) at screening and self-report of cannabis use Exclusion Criteria: - Unstable medical conditions: Heart disease; Uncontrolled hypertension; Thyroid disease (okay if controlled with medication); Diabetes; Hepatitis B or C or Liver disease; Glaucoma; Prostatic hypertrophy - Psychiatric conditions: Current or past schizophrenia, and/or current or past bipolar disorder; Adult onset attention deficit hyperactivity disorder (ADHD); Participants with current or past depression and/or anxiety disorders will be reviewed by the study physician and considered for inclusion; History of psychiatric hospitalizations are not exclusionary, but study participation will be determined as per study physician's approval - Concurrent regular use of smokeless tobacco or pipes [occasional users of these products may be enrolled if they agree to abstain from their use during the period of the study] - Medications: Use of medications that are inducers of nicotine metabolizing enzyme CYP2A6 (Example: rifampicin, dexamethasone, phenobarbital, and other anticonvulsant drugs).; Concurrent use of nicotine-containing medications; Psychiatric medications: current regular use of any psychiatric medications with the exception of Selective Serotonin Reuptake Inhibitors (SSRI) and serotonin-norepinephrine reuptake inhibitors (SNRI) and current evaluation by the study physician that the participant is otherwise healthy, stable, and able to participate. - Other/Misc. Chronic Health Conditions: Oral thrush; Fainting; Untreated thyroid disease; Other "life threatening illnesses" as per study physician's discretion - Pregnancy: Pregnancy (self-reported and urine pregnancy test); Breastfeeding (determined by self-report) - Drug/Alcohol Dependence: Alcohol or illicit drug dependence within the past 12 months with the exception of those who have recently completed an alcohol/drug treatment program; Positive toxicology test at the screening visit (THC & prescribed medications okay); Methadone replacement therapy - Concurrent participation in another clinical trial - Inability to communicate in English - History of marijuana-induced psychosis or paranoia after smoking marijuana - Scoring a 2 or higher on the Severity of Dependence Scale for cannabis use - Planning to quit smoking or vaping within the next 60 days

Study Design


Intervention

Other:
Smoked Cannabis
Cannabis will be purchased by the participants and reimbursed the full cost by the study. Participants will be asked to purchase enough to last 2 full days of use. To reduce variability between products, participants will be asked to purchase cannabis from one dispensary near the research facility (Purple Star MD at 2520 Mission St., San Francisco). Receipt must be provided to study staff.
Vaped Cannabis
Cannabis will be purchased by the participants and reimbursed the full cost by the study. Participants will be asked to purchase enough to last 2 full days of use. To reduce variability between products, participants will be asked to purchase cannabis from one dispensary near the research facility (Purple Star MD at 2520 Mission St., San Francisco). Receipt must be provided to study staff. All participants will use the study-provided PAX® (PAX 2) dry herb vaporizer, one of the most popular handheld vaporizers.
Tobacco Cigarette
Tobacco cigarettes of participants' choice (usual brand) will be provided by research staff for use on the study.

Locations

Country Name City State
United States University of California, San Francisco San Francisco California
United States Zuckerberg San Francisco General Hospital San Francisco California

Sponsors (2)

Lead Sponsor Collaborator
University of California, San Francisco Tobacco Related Disease Research Program

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Peak plasma concentration To assess the differences between smoked and vaped cannabis, we will determine maximum plasma THC concentration (Cmax) using plasma THC concentrations from the standardized sessions. Day 1 of each arm
Primary Time to peak plasma concentration To assess the differences of these variables between smoked and vaped cannabis, we will determine the time to max concentration (Tmax) using plasma THC concentrations from the standardized sessions. Day 1 of each arm
Primary Area under the plasma concentration versus time curve (AUC) To assess the differences of these variables between smoked and vaped cannabis, we will determine the AUC using plasma THC concentrations from the standardized sessions. Day 1 of each arm
Primary Subjective effects between cannabis products using the Marijuana Cravings Questionnaire We will assess measures from the Marijuana Cravings Questionnaire (MCQ) and compare them between smoked and vaped cannabis. Days 1-2 of each arm
Primary Subjective effects between cannabis products using the Visual Analog Scale We will assess measures from the Visual Analog Scale (VAS) and compare them between smoked and vaped cannabis. Days 1-2 of each arm
Primary Subjective effects between cannabis products using the Drug Effects Questionnaire We will assess measures from the Drug Effects Questionnaire (DEQ) and compare them between smoked and vaped cannabis. Days 1-2 of each arm
Primary Max change of expired carbon monoxide We will examine differences in max change of expired carbon monoxide (CO) from day 1 between smoked and vaped cannabis. Days 1-2 of the cannabis arms
Primary Area under the expired carbon monoxide (CO) curve (AUC) We will examine differences in integrated AUC of expired carbon monoxide from day 1 between smoked and vaped cannabis. Days 1-2 of the cannabis arms
Primary Differences in metabolites of volatile organic compounds (VOCs) We will examine differences in 12-hour urine mercapturic acid metabolites of volatile organic compounds (from day 2) between smoked and vaped cannabis. Days 1-2 of the cannabis arms
Primary Exposure to toxicants between cannabis products We will also examine how measures of use (number of puss, amount use, number of use episodes) correlate with biomarker concentrations between smoked and vaped cannabis. Days 1-2 of the cannabis arms
Primary Cardiovascular effects between cannabis products using heart rate as a measure We will compare maximum change in heart rate as well as an integrated measure of heart rate over the first 30 minutes after the standardized session (day 1) between smoked and vaped cannabis. Day 1 of each arm
Primary Cardiovascular effects between cannabis products using epinephrine as a measure Urine catecholamine excretion, particularly epinephrine, will be examined in 12-hour urines and compared between smoked and vaped cannabis. Day 2 of each cannabis arm
Primary Cardiovascular effects between cannabis products using platelet activation as a measure We will examine differences in blood and urine biomarkers of platelet activation between smoked and vaped cannabis. Day 2 of each cannabis arm
Primary Cardiovascular effects between cannabis products using oxidant stress as a measure We will examine differences in blood and urine biomarkers of oxidant stress between smoked and vaped cannabis. Day 2 of each cannabis arm
Primary Cardiovascular effects between cannabis products using endothelial dysfunction as a measure We will examine differences in blood and urine biomarkers of endothelial dysfunction and inflammation between smoked and vaped cannabis. Day 2 of each cannabis arm
Secondary Toxicant exposure between smoked tobacco and cannabis using expired carbon monoxide as the measure We will examine differences in expired carbon monoxide (CO) from day 1 (both max change and integrated AUC of expired CO) between smoked tobacco and cannabis. Day 1 of each arm
Secondary Toxicant exposure between smoked tobacco and cannabis using mercapturic acid as the measure We will examine differences in 12-hour urine mercapturic acid metabolites of volatile organic compounds (VOCs) (from day 2) between smoked tobacco and cannabis. Day 2 of each arm
Secondary Toxicant exposure between smoked tobacco and cannabis using use as a measure We will also examine how measures of use (number of puffs, amount use, number of use episodes) correlate with biomarker concentrations between smoked tobacco and cannabis. Days 1-2 of each arm
Secondary Cardiovascular effects between smoked tobacco and cannabis using heart rate as a measure We will compare maximum change in heart rate as well as an integrated measure of heart rate over the first 30 minutes after the standardized session (day 1) between smoked tobacco and cannabis. Day 1 of each arm
Secondary Cardiovascular effects between smoked tobacco and cannabis using epinephrine as a measure Urine catecholamine excretion, particularly epinephrine, will be examined in 12-hour urines. Day 2 of each arm
Secondary Cardiovascular effects between smoked tobacco and cannabis using platelet activation as a measure We will examine differences in blood and urine biomarkers of platelet activation between smoked tobacco and cannabis. Day 2 of each arm
Secondary Cardiovascular effects between smoked tobacco and cannabis using oxidant stress as a measure We will examine differences in blood and urine biomarkers of oxidant stress between smoked tobacco and cannabis. Day 2 of each arm
Secondary Cardiovascular effects between smoked tobacco and cannabis using endothelial dysfunction as a measure We will examine differences in blood and urine biomarkers of endothelial dysfunction and inflammation between smoked tobacco and cannabis. Day 2 of each arm
Secondary Puffing behaviors across all products We will examine how puffing behaviors are different between all products (smoked and vaped cannabis, as well as with smoked tobacco cigarettes) and how they correlate with toxicant biomarker concentrations. Vaping topography measures will be obtained from frame by frame analysis of high definition videos. Days 1-2 of each arm
See also
  Status Clinical Trial Phase
Recruiting NCT05176418 - IV Pulsed-Nicotine as a Model of Smoking: The Effects of Dose and Delivery Rate Early Phase 1
Completed NCT04084210 - Impact of Alternative Nicotine-Delivery Products on Combustible Cigarette Use Phase 2
Completed NCT04043728 - Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study N/A
Withdrawn NCT03707600 - State and Trait Mediated Response to TMS in Substance Use Disorder N/A
Recruiting NCT03999099 - Targeting Orexin to Treat Nicotine Dependence Phase 1
Completed NCT03847155 - Prevention of Nicotine Abstinence in Critically Ill Patients After Major Surgery N/A
Completed NCT02840435 - Study on Sit to Quit Phone Intervention N/A
Completed NCT02139930 - Project 2: Strategies for Reducing Nicotine Content in Cigarettes N/A
Completed NCT01982110 - A Mindfulness Based Application for Smoking Cessation N/A
Completed NCT01926626 - Evaluation of Moclobemide, a Reversible MAO-A Inhibitor, as an Adjunct to Nicotine Replacement Therapy in Female Smokers Phase 2
Completed NCT01632189 - The Effect of Varenicline on D2/D3 Receptor Binding in Smokers N/A
Withdrawn NCT01569477 - Striving to Quit-Wisconsin Tobacco Quit Line N/A
Completed NCT01685996 - Zonisamide Augmentation of Varenicline Treatment for Smoking Cessation Phase 1/Phase 2
Completed NCT01569490 - Striving to Quit: First Breath N/A
Active, not recruiting NCT01182766 - New Treatment for Alcohol and Nicotine Dependence Phase 2/Phase 3
Completed NCT01061528 - Coping Skills Treatment for Smoking Cessation N/A
Completed NCT00996034 - Nicotine Vaccination and Nicotinic Receptor Occupancy Phase 2
Withdrawn NCT01589081 - Effects of Progesterone on IV Nicotine-Induced Changes in Hormones and Subjective Ratings of Stimulant Drug Effect N/A
Suspended NCT01636336 - Effects of Progesterone on Smoked Nicotine Induced Changes in Hormones and Subjective Ratings of Stimulant Drug Effects N/A
Completed NCT01943994 - Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study N/A